Reuters logo
a month ago
BRIEF-Aimmune Therapeutics reports on up-dosing in its ongoing phase 3 palisade trial of ar101 for peanut allergy
June 12, 2017 / 8:09 PM / a month ago

BRIEF-Aimmune Therapeutics reports on up-dosing in its ongoing phase 3 palisade trial of ar101 for peanut allergy

1 Min Read

June 12 (Reuters) - Aimmune Therapeutics Inc:

* Aimmune Therapeutics reports on up-dosing in its ongoing phase 3 palisade trial of ar101 for peanut allergy

* Aimmune Therapeutics Inc - final study visits projected around year-end 2017; topline data expected in q1 of 2018

* Aimmune Therapeutics Inc - more than 97 percent of patients currently on study are through up-dosing phase Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below